DexCom (DXCM) Stock Forecast, Price Target & Predictions
DXCM Stock Forecast
DexCom stock forecast is as follows: an average price target of $81.86 (represents a 17.77% upside from DXCM’s last price of $69.51) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.
DXCM Price Target
The average price target for DexCom (DXCM) is $81.86 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $146.00 to $28.13. This represents a potential 17.77% upside from DXCM's last price of $69.51.
DXCM Analyst Ratings
According to 13 Wall Street analysts, DexCom's rating consensus is 'Buy'. The analyst rating breakdown for DXCM stock is 1 'Strong Buy' (7.69%), 10 'Buy' (76.92%), 2 'Hold' (15.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
DexCom Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 22, 2024 | Mathew Blackman | Stifel Nicolaus | $100.00 | $72.28 | 38.35% | 43.86% |
| Aug 16, 2024 | Shagun Singh | RBC Capital | $130.00 | $72.36 | 79.66% | 87.02% |
| Jul 29, 2024 | Matt Miksic | Barclays | $113.00 | $64.00 | 76.56% | 62.57% |
| Jul 26, 2024 | Steven Lichtman | Oppenheimer | $115.00 | $107.85 | 6.63% | 65.44% |
| Jul 26, 2024 | Matt O\'Brien | Piper Sandler | $90.00 | $63.22 | 42.36% | 29.48% |
| Jul 26, 2024 | William Plovanic | Canaccord Genuity | $89.00 | $107.85 | -17.48% | 28.04% |
| Jul 26, 2024 | Shagun Singh | RBC Capital | $145.00 | $63.55 | 128.17% | 108.60% |
| Jul 12, 2024 | Mathew Blackman | Stifel Nicolaus | $132.00 | $112.66 | 17.17% | 89.90% |
| Jun 03, 2024 | Steven Lichtman | Oppenheimer | $150.00 | $115.23 | 30.17% | 115.80% |
| May 30, 2024 | Issie Kirby | Redburn Partners | $130.00 | $127.64 | 1.85% | 87.02% |
The latest DexCom stock forecast, released on Aug 22, 2024 by Mathew Blackman from Stifel Nicolaus, set a price target of $100.00, which represents a 38.35% increase from the stock price at the time of the forecast ($72.28), and a 43.86% increase from DXCM last price ($69.51).
DexCom Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 8 | 12 |
| Avg Price Target | $115.00 | $114.25 | $123.42 |
| Last Closing Price | $69.51 | $69.51 | $69.51 |
| Upside/Downside | 65.44% | 64.36% | 77.56% |
In the current month, the average price target of DexCom stock is $115.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 65.44% increase as opposed to DexCom's last price of $69.51. This month's average price target is up 0.66% compared to last quarter, and down -6.82% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 26, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 23, 2024 | William Blair | Buy | Buy | Hold |
| Aug 23, 2024 | Wells Fargo | Underperform | Underperform | Hold |
| Aug 16, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 30, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| Jul 29, 2024 | Wells Fargo | Underperform | Underperform | Hold |
| Jul 29, 2024 | William Blair | Buy | Buy | Hold |
| Jul 29, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 26, 2024 | William Blair | Outperform | Outperform | Hold |
| Jul 26, 2024 | Oppenheimer | Outperform | Outperform | Hold |
DexCom's last stock rating was published by Piper Sandler on Aug 26, 2024. The company gave DXCM a "Overweight" rating, the same as its previous rate.
DexCom Financial Forecast
DexCom Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $1.03B | $975.00M | $871.30M | $741.50M | $815.20M | $769.60M | $696.20M | $628.80M | $698.20M | $650.20M | $595.10M | $505.00M | $568.90M | $500.90M | $451.80M | $405.10M | $462.80M | $396.30M |
| Avg Forecast | $1.52B | $1.43B | $1.36B | $1.27B | $1.28B | $1.17B | $1.14B | $1.04B | $1.10B | $989.24M | $1.04B | $909.93M | $1.02B | $939.64M | $841.16M | $720.71M | $810.10M | $751.80M | $697.50M | $623.87M | $697.47M | $618.65M | $551.67M | $486.59M | $553.01M | $500.90M | $416.62M | $358.55M | $441.02M | $347.89M |
| High Forecast | $1.53B | $1.44B | $1.37B | $1.28B | $1.30B | $1.19B | $1.15B | $1.05B | $1.11B | $1.00B | $1.05B | $920.18M | $1.03B | $948.40M | $850.64M | $728.82M | $819.22M | $760.27M | $705.37M | $630.91M | $705.35M | $625.63M | $557.90M | $492.09M | $559.25M | $506.56M | $421.33M | $362.60M | $446.00M | $351.82M |
| Low Forecast | $1.49B | $1.41B | $1.34B | $1.25B | $1.26B | $1.16B | $1.12B | $1.02B | $1.08B | $975.84M | $1.02B | $897.20M | $1.00B | $931.05M | $829.39M | $710.62M | $798.76M | $741.28M | $687.92M | $615.30M | $687.90M | $610.15M | $544.10M | $479.91M | $545.42M | $494.02M | $410.90M | $353.63M | $434.96M | $343.11M |
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 1 | 3 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.04% | 1.04% | 1.03% | 1.01% | 1.02% | 1.00% | 1.01% | 1.00% | 1.05% | 1.08% | 1.04% | 1.03% | 1.00% | 1.08% | 1.13% | 1.05% | 1.14% |
DexCom's average Quarter revenue forecast for Mar 24 based on 1 analysts is $909.93M, with a low forecast of $897.20M, and a high forecast of $920.18M. DXCM's average Quarter revenue forecast represents a -12.04% decrease compared to the company's last Quarter revenue of $1.03B (Dec 23).
DexCom EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 1 | 3 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $303.60M | $207.20M | $128.10M | $110.70M | $139.70M | $190.00M | $123.60M | $78.30M | $44.30M | $141.30M | $125.40M | $66.90M | $126.30M | $117.90M | $81.80M | $50.80M | $123.90M | $73.80M |
| Avg Forecast | $248.41M | $233.67M | $222.30M | $208.00M | $210.13M | $192.63M | $186.54M | $170.05M | $180.27M | $162.18M | $170.04M | $131.18M | $166.45M | $154.05M | $137.90M | $119.26M | $132.81M | $94.72M | $114.35M | $108.42M | $114.35M | $101.42M | $90.44M | $60.21M | $90.66M | $82.12M | $68.30M | $58.06M | $72.30M | $57.03M |
| High Forecast | $251.21M | $236.30M | $224.81M | $210.35M | $212.50M | $194.80M | $188.64M | $171.97M | $182.30M | $164.00M | $171.96M | $157.42M | $168.33M | $155.48M | $139.46M | $143.11M | $134.31M | $113.66M | $115.64M | $130.10M | $115.64M | $102.57M | $91.46M | $72.25M | $91.69M | $83.05M | $69.07M | $69.67M | $73.12M | $57.68M |
| Low Forecast | $244.94M | $230.40M | $219.19M | $205.09M | $207.19M | $189.94M | $183.93M | $167.67M | $177.75M | $159.98M | $167.66M | $104.95M | $164.12M | $152.64M | $135.97M | $95.41M | $130.95M | $75.77M | $112.78M | $86.73M | $112.78M | $100.03M | $89.20M | $48.17M | $89.42M | $80.99M | $67.37M | $46.45M | $71.31M | $56.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.82% | 1.35% | 0.93% | 0.93% | 1.05% | 2.01% | 1.08% | 0.72% | 0.39% | 1.39% | 1.39% | 1.11% | 1.39% | 1.44% | 1.20% | 0.88% | 1.71% | 1.29% |
1 analysts predict DXCM's average Quarter EBITDA for Mar 24 to be $131.18M, with a high of $157.42M and a low of $104.95M. This is -56.79% lower than DexCom's previous annual EBITDA (Dec 23) of $303.60M.
DexCom Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 1 | 3 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $256.30M | $120.70M | $115.90M | $48.60M | $91.80M | $101.20M | $50.90M | $97.30M | $-19.40M | $70.90M | $62.90M | $40.30M | $355.20M | $72.20M | $46.30M | $19.90M | $92.70M | $45.80M |
| Avg Forecast | $326.68M | $289.79M | $252.78M | $209.00M | $261.48M | $229.83M | $200.38M | $162.82M | $214.53M | $181.70M | $160.95M | $163.01M | $179.52M | $142.00M | $94.13M | $148.20M | $113.86M | $47.53M | $76.45M | $134.72M | $90.82M | $67.66M | $46.25M | $36.27M | $96.72M | $66.79M | $35.08M | $22.74M | $77.36M | $20.85M |
| High Forecast | $331.46M | $294.03M | $256.48M | $212.06M | $265.31M | $233.19M | $203.32M | $165.20M | $217.67M | $189.95M | $163.30M | $195.62M | $192.05M | $192.11M | $95.51M | $177.83M | $115.53M | $57.03M | $77.57M | $161.67M | $92.15M | $68.66M | $46.93M | $43.52M | $98.14M | $67.77M | $35.59M | $27.29M | $78.50M | $21.15M |
| Low Forecast | $320.74M | $284.52M | $248.18M | $205.20M | $256.72M | $225.65M | $196.74M | $159.86M | $210.63M | $165.18M | $158.02M | $130.41M | $162.82M | $108.58M | $92.41M | $118.56M | $111.79M | $38.02M | $75.09M | $107.78M | $89.20M | $66.45M | $45.42M | $29.02M | $95.00M | $65.60M | $34.45M | $18.19M | $75.98M | $20.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.43% | 0.85% | 1.23% | 0.33% | 0.81% | 2.13% | 0.67% | 0.72% | -0.21% | 1.05% | 1.36% | 1.11% | 3.67% | 1.08% | 1.32% | 0.88% | 1.20% | 2.20% |
DexCom's average Quarter net income forecast for Mar 24 is $163.01M, with a range of $130.41M to $195.62M. DXCM's average Quarter net income forecast represents a -36.40% decrease compared to the company's last Quarter net income of $256.30M (Dec 23).
DexCom SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 1 | 3 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $308.80M | $284.70M | $297.30M | $294.60M | $297.80M | $234.60M | $248.90M | $220.90M | $235.10M | $199.80M | $187.00M | $188.60M | $175.90M | $158.60M | $136.40M | $149.80M | $129.00M | $124.20M |
| Avg Forecast | $507.16M | $477.06M | $453.86M | $424.66M | $429.00M | $393.28M | $380.84M | $347.18M | $368.05M | $331.11M | $347.16M | $370.09M | $339.83M | $314.51M | $281.55M | $336.45M | $271.15M | $133.93M | $233.46M | $305.86M | $233.45M | $207.07M | $184.65M | $169.74M | $185.10M | $167.66M | $139.45M | $171.20M | $147.61M | $116.44M |
| High Forecast | $512.87M | $482.44M | $458.97M | $429.44M | $433.84M | $397.71M | $385.13M | $351.09M | $372.19M | $334.83M | $351.07M | $444.11M | $343.66M | $317.44M | $284.72M | $403.74M | $274.20M | $160.71M | $236.09M | $367.03M | $236.09M | $209.40M | $186.73M | $203.69M | $187.19M | $169.55M | $141.02M | $205.44M | $149.28M | $117.76M |
| Low Forecast | $500.06M | $470.39M | $447.51M | $418.72M | $423.00M | $387.77M | $375.51M | $342.32M | $362.90M | $326.62M | $342.30M | $296.07M | $335.08M | $311.63M | $277.61M | $269.16M | $267.35M | $107.14M | $230.25M | $244.69M | $230.25M | $204.22M | $182.11M | $135.79M | $182.56M | $165.36M | $137.53M | $136.96M | $145.59M | $114.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.91% | 1.06% | 0.88% | 1.10% | 1.75% | 1.07% | 0.72% | 1.01% | 0.96% | 1.01% | 1.11% | 0.95% | 0.95% | 0.98% | 0.88% | 0.87% | 1.07% |
DexCom's average Quarter SG&A projection for Mar 24 is $370.09M, based on 1 Wall Street analysts, with a range of $296.07M to $444.11M. The forecast indicates a 19.85% rise compared to DXCM last annual SG&A of $308.80M (Dec 23).
DexCom EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 1 | 3 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.31 | $0.30 | $0.13 | $0.24 | $0.26 | $0.13 | $0.25 | $-0.05 | $0.18 | $0.16 | $0.10 | $0.23 | $0.19 | $0.12 | $0.06 | $0.25 | $0.13 |
| Avg Forecast | $0.78 | $0.70 | $0.61 | $0.50 | $0.63 | $0.55 | $0.48 | $0.39 | $0.51 | $0.44 | $0.39 | $0.27 | $0.43 | $0.34 | $0.23 | $0.15 | $0.27 | $0.24 | $0.18 | $0.13 | $0.22 | $0.16 | $0.11 | $0.08 | $0.23 | $0.16 | $0.08 | $0.04 | $0.19 | $0.05 |
| High Forecast | $0.80 | $0.71 | $0.62 | $0.51 | $0.64 | $0.56 | $0.49 | $0.40 | $0.52 | $0.46 | $0.39 | $0.27 | $0.46 | $0.46 | $0.23 | $0.15 | $0.28 | $0.25 | $0.19 | $0.13 | $0.22 | $0.16 | $0.11 | $0.08 | $0.24 | $0.16 | $0.09 | $0.04 | $0.19 | $0.05 |
| Low Forecast | $0.77 | $0.68 | $0.60 | $0.49 | $0.62 | $0.54 | $0.47 | $0.38 | $0.51 | $0.40 | $0.38 | $0.26 | $0.39 | $0.26 | $0.22 | $0.14 | $0.27 | $0.24 | $0.18 | $0.13 | $0.21 | $0.16 | $0.11 | $0.08 | $0.23 | $0.16 | $0.08 | $0.04 | $0.18 | $0.05 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.33% | 0.89% | 0.88% | 1.06% | 0.71% | 1.91% | -0.23% | 1.12% | 1.46% | 1.36% | 1.00% | 1.17% | 1.46% | 1.47% | 1.36% | 2.50% |
According to 3 Wall Street analysts, DexCom's projected average Quarter EPS for Dec 23 is $0.43, with a low estimate of $0.39 and a high estimate of $0.46. This represents a 38.94% increase compared to DXCM previous annual EPS of $0.31 (Sep 23).
DexCom Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IART | Integra LifeSciences | $17.47 | $43.25 | 147.57% | Sell |
| TNDM | Tandem Diabetes Care | $43.97 | $84.44 | 92.04% | Buy |
| INMD | InMode | $17.04 | $31.40 | 84.27% | Hold |
| EW | Edwards Lifesciences | $68.52 | $97.09 | 41.70% | Buy |
| ZBH | Zimmer Biomet | $106.26 | $137.17 | 29.09% | Hold |
| MDT | Medtronic | $90.00 | $106.77 | 18.63% | Hold |
| DXCM | DexCom | $69.51 | $81.86 | 17.77% | Buy |
| PEN | Penumbra | $186.94 | $218.89 | 17.09% | Hold |
| INSP | Inspire Medical Systems | $203.99 | $237.80 | 16.57% | Buy |
| PODD | Insulet | $233.87 | $268.60 | 14.85% | Buy |
| ABT | Abbott Laboratories | $116.40 | $129.50 | 11.25% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |
DXCM Forecast FAQ
Is DexCom a good buy?
Yes, according to 13 Wall Street analysts, DexCom (DXCM) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 10 'Buy' recommendations, accounting for 84.62% of DXCM's total ratings.
What is DXCM's price target?
DexCom (DXCM) average price target is $81.86 with a range of $28.12 to $146, implying a 17.77% from its last price of $69.51. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will DexCom stock go up soon?
According to Wall Street analysts' prediction for DXCM stock, the company can go up by 17.77% (from the last price of $69.51 to the average price target of $81.86), up by 110.04% based on the highest stock price target, and down by -59.54% based on the lowest stock price target.
Can DexCom stock reach $100?
DXCM's highest twelve months analyst stock price target of $146 supports the claim that DexCom can reach $100 in the near future.
What is DexCom's current price target trend?
2 Wall Street analysts forecast a $115 price target for DexCom (DXCM) this month, up 65.44% from its last price of $69.51. Compared to the last 3 and 12 months, the average price target increased by 64.36% and increased by 77.56%, respectively.
What are DexCom's analysts' financial forecasts?
DexCom's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.63B (high $4.68B, low $4.57B), average EBITDA is $759.35M (high $767.9M, low $748.72M), average net income is $854.51M (high $867.02M, low $838.96M), average SG&A $1.55B (high $1.57B, low $1.53B), and average EPS is $2.05 (high $2.08, low $2.01). DXCM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $5.57B (high $5.63B, low $5.49B), average EBITDA is $912.39M (high $922.66M, low $899.62M), average net income is $1.08B (high $1.09B, low $1.06B), average SG&A $1.86B (high $1.88B, low $1.84B), and average EPS is $2.59 (high $2.62, low $2.54).
Did the DXCM's actual financial results beat the analysts' financial forecasts?
Based on DexCom's last annual report (Dec 2023), the company's revenue was $3.62B, beating the average analysts forecast of $3.52B by 3.00%. Apple's EBITDA was $916.7M, beating the average prediction of $577.66M by 58.69%. The company's net income was $541.5M, missing the average estimation of $563.84M by -3.96%. Apple's SG&A was $1.19B, missing the average forecast of $1.27B by -6.83%. Lastly, the company's EPS was $1.4, beating the average prediction of $1.14 by 22.45%. In terms of the last quarterly report (Dec 2023), DexCom's revenue was $1.03B, beating the average analysts' forecast of $1.02B by 1.89%. The company's EBITDA was $303.6M, beating the average prediction of $166.45M by 82.39%. DexCom's net income was $256.3M, beating the average estimation of $179.52M by 42.77%. The company's SG&A was $308.8M, missing the average forecast of $339.83M by -9.13%. Lastly, the company's EPS was $0, missing the average prediction of $0.431 by -100.00%